A phase I trial of adenoviral p53 gene therapy for non-small cell lung cancer

Toshiyoshi Fujiwara, M. Kataoka, O. Kawamata, N. Tanaka

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Lung cancer is one of the leading causes of cancer deaths worldwide. The high mortality rate for lung cancer results from the absence of standard therapeutic strategies, suggesting that lung cancer may be a suitable target disease for a novel gene-based therapy. Restoration of the function of a single pivotal gene product appears sufficient to mediate antitumor effects that are potentially clinically significant. Preclinical studies in animal models have demonstrated tumor regression following intratumoral administration of an adenovirus vector containing The wild-type tumor suppressor p53 gene. The efficacy and safety of the p53 gene therapy protocol for non-small cell lung cancer are now being evaluated in clinical trials. Although much research needs to be done following trials in the earliest stages, the treatment may offer a unique mechanism of action with a potentially high therapeutic index. This article reviews recent highlights in this rapidly evolving field.

Original languageEnglish
Pages (from-to)749-755
Number of pages7
JournalNippon Geka Gakkai zasshi
Volume100
Issue number11
Publication statusPublished - 1999

Fingerprint

p53 Genes
Non-Small Cell Lung Carcinoma
Genetic Therapy
Lung Neoplasms
Tumor Suppressor Genes
Adenoviridae
Cause of Death
Neoplasms
Therapeutics
Animal Models
Clinical Trials
Safety
Mortality
Research
Genes

Cite this

A phase I trial of adenoviral p53 gene therapy for non-small cell lung cancer. / Fujiwara, Toshiyoshi; Kataoka, M.; Kawamata, O.; Tanaka, N.

In: Nippon Geka Gakkai zasshi, Vol. 100, No. 11, 1999, p. 749-755.

Research output: Contribution to journalArticle

Fujiwara, T, Kataoka, M, Kawamata, O & Tanaka, N 1999, 'A phase I trial of adenoviral p53 gene therapy for non-small cell lung cancer', Nippon Geka Gakkai zasshi, vol. 100, no. 11, pp. 749-755.
Fujiwara, Toshiyoshi ; Kataoka, M. ; Kawamata, O. ; Tanaka, N. / A phase I trial of adenoviral p53 gene therapy for non-small cell lung cancer. In: Nippon Geka Gakkai zasshi. 1999 ; Vol. 100, No. 11. pp. 749-755.
@article{d46746e7e08f4300990903185e7f0e2c,
title = "A phase I trial of adenoviral p53 gene therapy for non-small cell lung cancer",
abstract = "Lung cancer is one of the leading causes of cancer deaths worldwide. The high mortality rate for lung cancer results from the absence of standard therapeutic strategies, suggesting that lung cancer may be a suitable target disease for a novel gene-based therapy. Restoration of the function of a single pivotal gene product appears sufficient to mediate antitumor effects that are potentially clinically significant. Preclinical studies in animal models have demonstrated tumor regression following intratumoral administration of an adenovirus vector containing The wild-type tumor suppressor p53 gene. The efficacy and safety of the p53 gene therapy protocol for non-small cell lung cancer are now being evaluated in clinical trials. Although much research needs to be done following trials in the earliest stages, the treatment may offer a unique mechanism of action with a potentially high therapeutic index. This article reviews recent highlights in this rapidly evolving field.",
author = "Toshiyoshi Fujiwara and M. Kataoka and O. Kawamata and N. Tanaka",
year = "1999",
language = "English",
volume = "100",
pages = "749--755",
journal = "Nihon Geka Gakkai zasshi",
issn = "0301-4894",
publisher = "Nihon Geka Gakkai",
number = "11",

}

TY - JOUR

T1 - A phase I trial of adenoviral p53 gene therapy for non-small cell lung cancer

AU - Fujiwara, Toshiyoshi

AU - Kataoka, M.

AU - Kawamata, O.

AU - Tanaka, N.

PY - 1999

Y1 - 1999

N2 - Lung cancer is one of the leading causes of cancer deaths worldwide. The high mortality rate for lung cancer results from the absence of standard therapeutic strategies, suggesting that lung cancer may be a suitable target disease for a novel gene-based therapy. Restoration of the function of a single pivotal gene product appears sufficient to mediate antitumor effects that are potentially clinically significant. Preclinical studies in animal models have demonstrated tumor regression following intratumoral administration of an adenovirus vector containing The wild-type tumor suppressor p53 gene. The efficacy and safety of the p53 gene therapy protocol for non-small cell lung cancer are now being evaluated in clinical trials. Although much research needs to be done following trials in the earliest stages, the treatment may offer a unique mechanism of action with a potentially high therapeutic index. This article reviews recent highlights in this rapidly evolving field.

AB - Lung cancer is one of the leading causes of cancer deaths worldwide. The high mortality rate for lung cancer results from the absence of standard therapeutic strategies, suggesting that lung cancer may be a suitable target disease for a novel gene-based therapy. Restoration of the function of a single pivotal gene product appears sufficient to mediate antitumor effects that are potentially clinically significant. Preclinical studies in animal models have demonstrated tumor regression following intratumoral administration of an adenovirus vector containing The wild-type tumor suppressor p53 gene. The efficacy and safety of the p53 gene therapy protocol for non-small cell lung cancer are now being evaluated in clinical trials. Although much research needs to be done following trials in the earliest stages, the treatment may offer a unique mechanism of action with a potentially high therapeutic index. This article reviews recent highlights in this rapidly evolving field.

UR - http://www.scopus.com/inward/record.url?scp=0033217461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033217461&partnerID=8YFLogxK

M3 - Article

VL - 100

SP - 749

EP - 755

JO - Nihon Geka Gakkai zasshi

JF - Nihon Geka Gakkai zasshi

SN - 0301-4894

IS - 11

ER -